HRP20140780T4 - Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze - Google Patents

Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze Download PDF

Info

Publication number
HRP20140780T4
HRP20140780T4 HRP20140780TT HRP20140780T HRP20140780T4 HR P20140780 T4 HRP20140780 T4 HR P20140780T4 HR P20140780T T HRP20140780T T HR P20140780TT HR P20140780 T HRP20140780 T HR P20140780T HR P20140780 T4 HRP20140780 T4 HR P20140780T4
Authority
HR
Croatia
Prior art keywords
weight
pharmaceutical preparation
hemitartrate
salt
preparation according
Prior art date
Application number
HRP20140780TT
Other languages
English (en)
Croatian (hr)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P. Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140780(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of HRP20140780T1 publication Critical patent/HRP20140780T1/hr
Publication of HRP20140780T4 publication Critical patent/HRP20140780T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
HRP20140780TT 2009-11-27 2010-11-24 Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze HRP20140780T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
EP10785289.9A EP2504332B2 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Publications (2)

Publication Number Publication Date
HRP20140780T1 HRP20140780T1 (en) 2014-11-07
HRP20140780T4 true HRP20140780T4 (hr) 2021-08-06

Family

ID=43431870

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20140780TT HRP20140780T4 (hr) 2009-11-27 2010-11-24 Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze
HRP20161038TT HRP20161038T1 (hr) 2009-11-27 2016-08-17 Genz 112638 za liječenje gaucherove ili fabrijeve bolesti u kombiniranoj terapiji
HRP20191647 HRP20191647T1 (hr) 2009-11-27 2019-09-12 Eliglustat (genz 112638) kao inhibitor glukozilceramid sintaze za uporabu u postupku liječenja fabryjeve ili gaucherove bolesti, postupak sadrži podešavanje pojedinačne terapeutske doze metabolizmu p-450 kod pacijenta

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20161038TT HRP20161038T1 (hr) 2009-11-27 2016-08-17 Genz 112638 za liječenje gaucherove ili fabrijeve bolesti u kombiniranoj terapiji
HRP20191647 HRP20191647T1 (hr) 2009-11-27 2019-09-12 Eliglustat (genz 112638) kao inhibitor glukozilceramid sintaze za uporabu u postupku liječenja fabryjeve ili gaucherove bolesti, postupak sadrži podešavanje pojedinačne terapeutske doze metabolizmu p-450 kod pacijenta

Country Status (40)

Country Link
US (7) US11458119B2 (enExample)
EP (5) EP2504332B2 (enExample)
JP (6) JP2013512252A (enExample)
KR (6) KR20180049255A (enExample)
CN (5) CN112521367B (enExample)
AR (3) AR079152A1 (enExample)
AU (3) AU2010324810B2 (enExample)
BR (1) BR112012012947B8 (enExample)
CA (3) CA3075788C (enExample)
CL (2) CL2012001348A1 (enExample)
CR (1) CR20120277A (enExample)
CY (3) CY1115880T1 (enExample)
DK (3) DK2504332T4 (enExample)
DO (2) DOP2012000141A (enExample)
EA (3) EA023923B1 (enExample)
EC (2) ECSP12011926A (enExample)
ES (4) ES2754398T3 (enExample)
GT (1) GT201200161A (enExample)
HR (3) HRP20140780T4 (enExample)
HU (2) HUE045784T2 (enExample)
IL (4) IL310635A (enExample)
LT (2) LT3133070T (enExample)
MA (1) MA33838B1 (enExample)
ME (1) ME02477B (enExample)
MX (2) MX381242B (enExample)
MY (2) MY192644A (enExample)
NI (1) NI201200096A (enExample)
NZ (3) NZ600155A (enExample)
PE (2) PE20121337A1 (enExample)
PH (2) PH12015502514B1 (enExample)
PL (4) PL3133070T3 (enExample)
PT (4) PT2504332E (enExample)
RS (3) RS53503B2 (enExample)
SG (2) SG10201407881WA (enExample)
SI (3) SI3133070T1 (enExample)
SM (1) SMT201600273B (enExample)
TN (1) TN2012000237A1 (enExample)
TW (3) TWI586663B (enExample)
UA (1) UA113491C2 (enExample)
WO (1) WO2011066352A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
MY192644A (en) 2009-11-27 2022-08-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
ES2664844T3 (es) * 2011-06-20 2018-04-23 Mount Sinai School Of Medicine Tratamiento dirigido contra TNF para las mucopolisacaridosis y otros trastornos lisosómicos
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
ES2786128T3 (es) 2012-06-01 2020-10-08 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
CN110372636B (zh) * 2013-09-20 2023-03-28 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
CA2954030A1 (en) * 2014-07-03 2016-01-07 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
SG11201911859QA (en) 2017-06-16 2020-01-30 Beta Pharma Inc Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
WO2019030645A1 (en) 2017-08-08 2019-02-14 Kashiv Pharma Llc Pharmaceutical composition comprising eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
IL275091B2 (en) * 2017-12-15 2024-09-01 Genzyme Corp Methods for treating gaucher disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
KR20210024492A (ko) * 2018-05-27 2021-03-05 바이오아시스 테크놀로지스 인크. 고쉐병의 치료
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
EP4366737A1 (en) * 2021-07-05 2024-05-15 Asceneuron SA Medicaments comprising glycosidase inhibitors
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease
EP4725474A1 (en) 2024-10-11 2026-04-15 Genepharm S.A. A solid composition of eliglustat

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
CN1128951A (zh) 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
ES2149350T3 (es) 1994-02-02 2000-11-01 Liposome Co Inc Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion.
CA2192555C (en) 1994-06-10 2005-01-11 Jinichi Inokuchi 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6511979B1 (en) 1998-07-27 2003-01-28 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
IL152411A0 (en) 2000-04-24 2003-05-29 Teva Pharma Zolpidem hemitartrate
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2002057435A2 (en) * 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
US6855830B2 (en) 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
US7371772B2 (en) 2001-08-08 2008-05-13 Takeda Pharmaceutical Company Limited Bicyclic compound, production and use thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
ATE504588T1 (de) * 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
BRPI0516001A (pt) 2004-10-13 2008-08-19 Pharmacia & Upjohn Co Llc formas cristalinas de 3-[5-cloro-4-[(2, 4-difluorobenzil) óxi]-6-oxopirimidin-1(6h)-il]-n-(2-hidroxietil)-4-metilben zamida
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
US20070088082A1 (en) * 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
US20080293946A1 (en) * 2005-10-03 2008-11-27 Cheng Brian K Process for Preparing Zolpidem Hemitartrate and Tartrate Polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
ES2546181T3 (es) * 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2117518A2 (en) * 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Tablet-in-tablet compositions
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307181A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
MY192644A (en) 2009-11-27 2022-08-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
JP2014517049A (ja) 2011-06-21 2014-07-17 ノバルティス アーゲー （ｓ）−ピロリジン−１，２−ジカルボン酸２−アミド１−（｛４−メチル−５−［２−（２，２，２−トリフルオロ−１，１−ジメチル−エチル）−ピリジン−４−イル］−チアゾール−２−イル｝−アミドの多形
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
CN112521366A (zh) 2021-03-19
JP2013512252A (ja) 2013-04-11
LT2796457T (lt) 2016-09-12
KR20200013105A (ko) 2020-02-05
US20130137743A1 (en) 2013-05-30
PT3133070T (pt) 2019-11-11
DK2504332T4 (da) 2021-06-07
DOP2012000141A (es) 2012-09-30
AR121612A2 (es) 2022-06-22
JP6452635B2 (ja) 2019-01-16
PL2504332T5 (pl) 2021-08-23
EP2796457A1 (en) 2014-10-29
EP2504332B1 (en) 2014-06-04
JP2023116764A (ja) 2023-08-22
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
DK3133070T3 (da) 2019-11-11
CA3075788C (en) 2021-12-21
HRP20191647T1 (hr) 2019-12-13
HUE029371T2 (en) 2017-02-28
NZ715108A (en) 2017-06-30
MY192644A (en) 2022-08-29
EA029990B1 (ru) 2018-06-29
MA33838B1 (fr) 2012-12-03
RS59543B1 (sr) 2019-12-31
KR20180049255A (ko) 2018-05-10
DK2796457T3 (en) 2016-08-29
WO2011066352A8 (en) 2011-08-11
US20160166542A1 (en) 2016-06-16
ECSP18063798A (es) 2020-02-28
HRP20140780T1 (en) 2014-11-07
AU2017265180B2 (en) 2019-08-01
BR112012012947A2 (pt) 2017-03-01
ECSP12011926A (es) 2012-07-31
PE20171255A1 (es) 2017-08-28
SG10201407881WA (en) 2015-01-29
JP2015212291A (ja) 2015-11-26
SG10201800136QA (en) 2018-02-27
CN105753846B (zh) 2019-11-15
ES2586947T3 (es) 2016-10-19
TW201737910A (zh) 2017-11-01
PH12015502514B1 (en) 2022-07-29
TW201130822A (en) 2011-09-16
MY160542A (en) 2017-03-15
KR20220162824A (ko) 2022-12-08
CL2016002589A1 (es) 2017-05-19
US20160120842A1 (en) 2016-05-05
HUE045784T2 (hu) 2020-01-28
CN112521367B (zh) 2024-01-02
ES2493940T3 (es) 2014-09-12
US20230172903A1 (en) 2023-06-08
PH12012501048A1 (en) 2013-02-04
UA113491C2 (xx) 2017-02-10
KR20250005503A (ko) 2025-01-09
EP3896069A1 (en) 2021-10-20
EP3599237B1 (en) 2021-03-24
MX381242B (es) 2025-03-12
US20210369672A1 (en) 2021-12-02
NI201200096A (es) 2012-10-30
CY1122698T1 (el) 2021-03-12
JP2019001809A (ja) 2019-01-10
SI2504332T2 (sl) 2021-08-31
RS53503B2 (sr) 2021-07-30
JP6370264B2 (ja) 2018-08-08
EP3599237A1 (en) 2020-01-29
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
DK2504332T3 (da) 2014-08-25
IL219892A0 (en) 2012-07-31
TWI586663B (zh) 2017-06-11
CL2012001348A1 (es) 2012-08-24
TWI656873B (zh) 2019-04-21
AU2016202591B2 (en) 2017-11-30
CN102712629A (zh) 2012-10-03
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
CA2781676A1 (en) 2011-06-03
PL2504332T3 (pl) 2014-10-31
EP3133070A1 (en) 2017-02-22
SMT201600273B (it) 2016-08-31
SI2796457T1 (sl) 2016-10-28
EA201890254A3 (ru) 2019-02-28
IL260299A (en) 2018-08-30
SI3133070T1 (sl) 2019-11-29
EA201592195A1 (ru) 2016-04-29
NZ600155A (en) 2014-10-31
EP3133070B1 (en) 2019-08-14
IL283935A (en) 2021-07-29
RS54978B1 (sr) 2016-11-30
US12465586B2 (en) 2025-11-11
PL3133070T3 (pl) 2020-01-31
US20260115165A1 (en) 2026-04-30
JP7150528B2 (ja) 2022-10-11
TN2012000237A1 (en) 2013-12-12
HK1203485A1 (en) 2015-10-30
BR112012012947B1 (pt) 2021-04-06
ES2875382T3 (es) 2021-11-10
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
DOP2016000250A (es) 2017-02-15
AU2017265180A1 (en) 2017-12-14
EA023923B1 (ru) 2016-07-29
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
AU2010324810A1 (en) 2012-06-07
CY1115880T1 (el) 2017-01-25
US10888547B2 (en) 2021-01-12
HRP20161038T1 (hr) 2016-10-21
PH12015502514A1 (en) 2016-08-15
LT3133070T (lt) 2019-11-11
PL2796457T3 (pl) 2017-04-28
GT201200161A (es) 2014-01-27
MX2012006083A (es) 2012-06-19
EA201270646A1 (ru) 2013-01-30
EP2504332B2 (en) 2021-03-17
IL310635A (en) 2024-04-01
CN102712629B (zh) 2016-10-12
CN112521367A (zh) 2021-03-19
CY1117996T1 (el) 2017-05-17
PT2796457T (pt) 2016-07-14
AR079152A1 (es) 2011-12-28
EA201890254A2 (ru) 2018-10-31
PT3599237T (pt) 2021-04-28
KR20150125734A (ko) 2015-11-09
CN105777707B (zh) 2020-10-13
PT2504332E (pt) 2014-09-02
CA3075788A1 (en) 2011-06-03
ME02477B (me) 2017-02-20
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
KR20120115972A (ko) 2012-10-19
TW201639562A (zh) 2016-11-16
CA3140959A1 (en) 2011-06-03
WO2011066352A1 (en) 2011-06-03
BR112012012947B8 (pt) 2021-05-25
RS53503B1 (sr) 2015-02-27
CA2781676C (en) 2020-05-05
ES2493940T5 (es) 2021-11-23
SI2504332T1 (sl) 2014-09-30
ES2754398T3 (es) 2020-04-17
US11458119B2 (en) 2022-10-04
PL3599237T3 (pl) 2021-09-27
JP2020189873A (ja) 2020-11-26
HK1172031A1 (en) 2013-04-12
EP2796457B1 (en) 2016-05-18
EP2504332A1 (en) 2012-10-03
JP2016138124A (ja) 2016-08-04

Similar Documents

Publication Publication Date Title
HRP20191094T1 (hr) Formulacije 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
HRP20191647T1 (hr) Eliglustat (genz 112638) kao inhibitor glukozilceramid sintaze za uporabu u postupku liječenja fabryjeve ili gaucherove bolesti, postupak sadrži podešavanje pojedinačne terapeutske doze metabolizmu p-450 kod pacijenta
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
HRP20230931T1 (hr) Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida
DK2582366T3 (en) A pharmaceutical combination for the treatment of pain.
FI3067043T3 (fi) Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
JP2006298933A5 (enExample)
WO2008144730A3 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
JP2018513852A5 (enExample)
NO343505B1 (no) Farmasøytisk kombinasjon omfattende 3-(3-dimetylamino-1-etyl-2-metylpropyl)-fenyl og paracetamol
JP2006516648A5 (enExample)
HRP20211862T1 (hr) Pripravci za i postupci liječenja anemije
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
HRP20120938T1 (hr) Derivati benzotiazepina kao inhibitori receptora za rianodin (ryr2) i njihova uporaba u lijeäśenju sräśanih bolesti
JP2012520883A5 (enExample)
UA116334C2 (uk) Тверді форми дозування бендамустину
RU2012142811A (ru) Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
HRP20240115T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
WO2008116601A3 (en) Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
JP2011516544A5 (enExample)
HRP20201736T1 (hr) Postupak liječenja diskinezije
CA2964684A1 (en) Composition for the treatment of conditions involving muscular pain
JP2015516447A (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ−［３，４，ｂ］インドール］−４−アミンおよびプロピオン酸誘導体を含む医薬組成物
JP6015116B2 (ja) 錠剤及びその製造方法